1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Pilot Projects Program (COBRE in Aging and Regenerative Medicine) is sponsored by Tulane Center for Aging. The COBRE in Aging and Regenerative Medicine at Tulane University has a robust Pilot Projects Program.
Their research theme encompasses aging and regenerative medicine, with a focus on understanding the interplay between aging, chronic disease, degeneration, stem cell function, neurocognitive aging, neuroinflammation, metabolic regulation, and inflammaging. Research in chronic pain and epigenetics of aging would be relevant.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Investigators with a dedicated, project-specific mentor (likely affiliated with Tulane University or collaborating institutions, further details needed). Confirm the full requirements in the official notice before applying.
Pilot Projects Program (COBRE in Aging and Regenerative Medicine) is funded by Tulane Center for Aging. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Seven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read articleARPA-H awarded $144M across 7 research teams to run the first clinical trials treating aging as a condition — not a disease. How PROSPR reshapes longevity funding and what grant seekers in biotech, academia, and health tech should know.
Read article